Some direct AMPK activators have been slated for human clinical trials for type 2 diabetes [55], and it remains unclear whether the beneficial effects of long-term salicylate treatment on insulin resistance are mediated by inhibiting of NF-κB signaling, by AMPK activation, or by a combination of these pathways [56]. Here, PRKAA1 is linked to Insulin resistance.